Vaccitech price target lowered to $7 from $23 at Barclays

Barclays analyst Carter Gould lowered the firm’s price target on Vaccitech to $7 from $23 and keeps an Overweight rating on the shares. The firm said in a research note on Friday that the price target decrease reflects a story limited to VTP-300 and VTP-200 for now, with the potential for inflection in the share price likely more muted than it previously thought and likely limited to VTP-300 combination data.